For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside ...

A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...

Lung cancer is the top cause of cancer-related deaths globally, more prevalent in men, and ranks third among women. Both ...

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

November is Lung Cancer Awareness Month, and early detection is in the air. According to the Centers for Disease Control, ...

Sino Biopharmaceutical (HK:1177) has released an update. Sino Biopharmaceutical has received approval from the U.S. FDA to commence Phase I ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...

Adenocarcinoma is the most common type of lung cancer in people who have never smoked. 8 In this patient cohort, a ...

Dr Anthony Cunliffe discusses a case of lung cancer that was identified in a non-smoking patient with unusual symptoms ...

Robust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastasesTop-line pivotal data ...